Celldex Therapeutics Inc
(NAS:CLDX)
$
25.43
0.04 (0.16%)
Market Cap: 1.69 Bil
Enterprise Value: 883.77 Mil
PE Ratio: 0
PB Ratio: 2.07
GF Score: 63/100 
Celldex Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023 / 01:00PM GMT
Release Date Price:
$35.23
(+0.74%)
Chris Howerton
(Trades, Portfolio), Inc. - Moderator
We have the Celldex team here, and we're hoping to talk about a little bit of KIT, so let's get started. Anthony, maybe you could get us started in terms of barzolvolimab? And where do you see that in terms of the KIT space?
Questions & Answers
Anthony Marucci
Celldex Therapeutics, Inc. - President, CEO, Director, Founder
Sure. So barzo is currently in two Phase-2 studies, one in chronic spontaneous urticaria, and the other in CindU or chronic inducible urticaria. The Phase-2 studies are currently enrolling. We also have completed a Phase 1b PN study, and that we are planning to put that into Phase 2 sometime later this year or the early part of '24.
The EoE study just initiated the
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers